clinical trial · NCT06349759
Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances
Ocuphire Pharma, Inc.·phase3·completed·n = 200
Mesopic VisionNight Vision Lossphentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonistPlacebo
brief summary
Safety and efficacy of 0.75% Phentolamine Ophthalmic Solution to improve mesopic low contrast visual acuity in subjects with post-refractive surgery visual disturbances.
started
Apr 1, 2024
primary completion
Apr 17, 2025
completion
Feb 19, 2026
last updated
Mar 12, 2026
detailed description
Randomized, placebo-controlled, double-masked study of the safety and efficacy of POS (0.75% Phentolamine Ophthalmic Solution) in subjects who have previously had keratorefractive surgery and have decreased visual acuity (VA) under mesopic conditions
official title
Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of POS (0.75% Phentolamine Ophthalmic Solution) in Subjects Who Have Previously Had Keratorefractive Surgery and Have Decreased Visual Acuity Under Mesopic Conditions
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol